104 related articles for article (PubMed ID: 16762510)
41. The role of chemotherapy and radiation in the management of biliary cancer: a review of the literature.
Hejna M; Pruckmayer M; Raderer M
Eur J Cancer; 1998 Jun; 34(7):977-86. PubMed ID: 9849443
[TBL] [Abstract][Full Text] [Related]
42. Molecular Characteristics of Biliary Tract and Primary Liver Tumors.
Tsai S; Gamblin TC
Surg Oncol Clin N Am; 2019 Oct; 28(4):685-693. PubMed ID: 31472913
[TBL] [Abstract][Full Text] [Related]
43. Matching genomic molecular aberrations with molecular targeted agents: Are biliary tract cancers an ideal playground?
Verlingue L; Hollebecque A; Boige V; Ducreux M; Malka D; Ferté C
Eur J Cancer; 2017 Aug; 81():161-173. PubMed ID: 28628842
[TBL] [Abstract][Full Text] [Related]
44. Second-line chemotherapy in advanced biliary cancer: the present now will later be past.
Vivaldi C; Fornaro L; Cereda S; Aprile G; Santini D; Silvestris N; Lonardi S; Leone F; Milella M; Brandi G; Vasile E
Ann Oncol; 2014 Dec; 25(12):2443-2444. PubMed ID: 25122694
[No Abstract] [Full Text] [Related]
45. ASO Author Reflections: Hypoxia-Induced PLOD2 Is a Key Regulator in Epithelial-Mesenchymal Transition and Chemoresistance in Biliary Tract Cancer.
Okumura Y; Eguchi H
Ann Surg Oncol; 2018 Nov; 25(12):3738-3739. PubMed ID: 30167909
[No Abstract] [Full Text] [Related]
46. Reply to the letter to the editor 'second-line chemotherapy in advanced biliary cancer: the present now will later be past' by Vivaldi et al.
Lamarca A; Hubner RA; Ryder WD; Valle JW
Ann Oncol; 2014 Dec; 25(12):2444-2445. PubMed ID: 25139549
[No Abstract] [Full Text] [Related]
47. Emerging drugs for biliary cancer.
Okusaka T; Ojima H; Morizane C; Ikeda M; Shibata T
Expert Opin Emerg Drugs; 2014 Mar; 19(1):11-24. PubMed ID: 24354562
[TBL] [Abstract][Full Text] [Related]
48. How do we choose the appropriate chemotherapeutic agents for biliary tract cancer?
Neureiter D; Mayr C; Kiesslich T
Expert Opin Pharmacother; 2020 Feb; 21(3):243-245. PubMed ID: 31899989
[No Abstract] [Full Text] [Related]
49. A foreword on biliary tract cancers: emerging treatments, drug targets, and fundamental knowledge gaps.
Rizzo A; Brandi G
Expert Opin Investig Drugs; 2021 Apr; 30(4):279. PubMed ID: 33678120
[No Abstract] [Full Text] [Related]
50. Paving a pathway for drug development in HER2-positive biliary tract cancer.
Chen CT; Goyal L
Lancet Oncol; 2021 Sep; 22(9):1204-1206. PubMed ID: 34478661
[No Abstract] [Full Text] [Related]
51. What is the value of the 21-gene recurrence score?
Brauchli P; Thürlimann B; Crowe SN; Herrmann R
J Clin Oncol; 2010 Nov; 28(32):e671-2; author reply 673-4. PubMed ID: 20805445
[No Abstract] [Full Text] [Related]
52. The scope of radical surgery in the treatment of malignant tumors of the extrahepatic biliary tract.
GLENN F; HAYS DM
Surg Gynecol Obstet; 1954 Nov; 99(5):529-41. PubMed ID: 13205425
[No Abstract] [Full Text] [Related]
53. [Surgical procedures and results in cancers of the biliary tract].
CERIANI BP
An Paul Med Cir; 1958 May; 75(5):305-14. PubMed ID: 13571625
[No Abstract] [Full Text] [Related]
54. [Neoplastic jaundices and cancers of the biliary tract. Introduction].
CAROLI J
Rev Prat; 1960 Sep; 10():2449. PubMed ID: 13690930
[No Abstract] [Full Text] [Related]
55. Intrahepatic cholangiocarcinoma and gallbladder cancer: distinguishing molecular profiles to guide potential therapy.
Potkonjak M; Miura JT; Turaga KK; Johnston FM; Tsai S; Christians KK; Gamblin TC
HPB (Oxford); 2015 Dec; 17(12):1119-23. PubMed ID: 26374242
[TBL] [Abstract][Full Text] [Related]
56. Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial.
Bengala C; Bertolini F; Malavasi N; Boni C; Aitini E; Dealis C; Zironi S; Depenni R; Fontana A; Del Giovane C; Luppi G; Conte P
Br J Cancer; 2010 Jan; 102(1):68-72. PubMed ID: 19935794
[TBL] [Abstract][Full Text] [Related]
57. Effect of histone deacetylase inhibitor on proliferation of biliary tract cancer cell lines.
Xu LN; Wang X; Zou SQ
World J Gastroenterol; 2008 Apr; 14(16):2578-81. PubMed ID: 18442209
[TBL] [Abstract][Full Text] [Related]
58. Biliary tract cancers: molecular profiling as a tool for treatment decisions. A literature review.
Berardi R; Scartozzi M; Freddari F; Squadroni M; Santinelli A; Bearzi I; Fabris G; Cascinu S
Cancer Treat Rev; 2006 Aug; 32(5):333-47. PubMed ID: 16762510
[TBL] [Abstract][Full Text] [Related]
59. Emerging treatment with systemic chemotherapy and targeted agents for biliary cancers.
Boku N
Curr Opin Investig Drugs; 2010 Jun; 11(6):653-60. PubMed ID: 20496260
[TBL] [Abstract][Full Text] [Related]
60. Biological characteristics of cancers in the gallbladder and biliary tract and targeted therapy.
Thomas MB
Crit Rev Oncol Hematol; 2007 Jan; 61(1):44-51. PubMed ID: 17164111
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
